Article
Astralis Ltd., partnered with SkyPharma PLC, has initiated a phase I clinical trial in the United States for Psoraxine, a new injectable treatment for moderate psoriasis.
Conference Recap: 2024 Society of Dermatology Physician Associates Fall Dermatology Conference
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
New Algorithm Proposes Targeted Lipase Monitoring for Pancreatic Adverse Events In Melanoma
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Protagonist Introduces Oral Peptide IL-17 Antagonist PN-881
Review Compares Psoriasis Therapies in Asian Populations